AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA”
Nov. 22, 2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA

Featured image for “Meaning-Centered Psychotherapy for Cancer Patients”
Nov. 22, 2024

Meaning-Centered Psychotherapy for Cancer Patients

Featured image for “Crafting Hope: Chris Krizek’s Journey from Cancer Patient to AIM Fundraiser with Wine Cork Creations”
Nov. 05, 2024

Crafting Hope: Chris Krizek’s Journey from Cancer Patient to AIM Fundraiser with Wine Cork Creations

Featured image for “Book Suggestions for Caregivers”
Nov. 04, 2024

Book Suggestions for Caregivers

Featured image for “Turn Hope into Action with AIM at Melanoma”
Oct. 28, 2024

Turn Hope into Action with AIM at Melanoma

Filter by Tag